Avita Medical Inc.
RCEL · NASDAQ
Market closed$5.10$0.120000 (+2.41%)After hours $4.72 · -7.45%
Key statistics
Previous close$4.98
Open$4.98
Day high$5.12
Day low$4.72
52-week high$7.12
52-week low$3.22
Market cap126.70M
Volume293.65K
Average volume298.02K
P/E ratio-3.25
Forward P/E—
EPS-1.57
Dividend yield0.00%
Market context
Why it moved
RCEL shares moved higher on moderate volume, likely driven by broader market optimism and renewed investor interest in the regenerative medicine space amid positive sector sentiment.
What is happening
Recent company-specific developments and publisher coverage.
Simply Wall Street · July 13, 2026RCEL: Renewed Adoption Confidence Will Support Future Bullish RepricingMoomoo · June 26, 2026Lake Street Maintains Avita Medical(RCEL.US) With Buy Rating, Maintains Target Price $6Stock Titan · June 18, 2026AVITA Medical’s burn treatment used in 17 U.K. patientsStock Titan · May 17, 2026Two AVITA Medical investor Q&As with CEO Cary Vance on May 20–21Investing News Network · May 14, 2026AVITA Medical Reports First Quarter 2026 Financial ResultsInvesting News Network · April 14, 2026AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin GraftingSeeking Alpha · April 9, 2026AVITA Medical: Why The BARDA Rally Changes Nothing (NASDAQ:RCEL)Investing News Network · January 13, 2026AVITA Medical: Pre-J.P. Morgan Update Highlights 2025 Revenue Growth, New Debt Facility, and 2026 Growth Outlook Benzinga · May 15, 2026Lake Street Upgrades AVITA Medical to Buy, Raises Price Target to $6 Benzinga · May 14, 2026AVITA Medical Reports Q1 2026 Results: Full Earnings Call Transcript Mt Newswire · May 14, 2026AVITA Medical Q1 Loss Narrows, Revenue Rises; 2026 Revenue Guidance Reaffirmed Benzinga · May 14, 2026AVITA Medical Q1 EPS $(0.35) Misses $(0.28) Estimate, Sales $19.251M Beat $18.175M Estimate Mt Newswire · April 30, 2026AVITA Medical Names Cary Vance as CEO Benzinga · April 30, 2026AVITA Medical Appoints Cary Vance President, CEO; Jan Stern As Board Chair, Effective Immediately Benzinga · April 14, 2026AVITA Medical Announces Data From Cohealyx-I Multi-Center Trial Shows Reduction Of ~20 Days In Mean Time To Skin Grafting For Participants With Full-Thickness Wounds Mt Newswire · April 8, 2026Avita Medical Signs 10-Year BARDA Agreement Valued Up to $25.5 Million